SuperCAP Program to Improve Cognition and Daily Functioning in Post-COVID-19 Condition
Randomized Controlled Trial to Assess the Efficacy of a Supervised Computerized Active Program (SuperCAP) to Improve Cognition and Daily Functioning in People With Post-COVID-19 Condition
1 other identifier
interventional
100
1 country
1
Brief Summary
The goal of this study is to determine whether the SuperCAP intervention program is superior to control in reducing disability from baseline to the post-intervention assessment in people with Post-COVID-19 Condition. The main question it aims to answer is whether participants assigned to SuperCAP experience a greater reduction in disability, defined as an improvement of at least 5 points on the WHODAS 2.0 from baseline to the post-intervention visit, compared with participants in the control group. Participants assigned to the SuperCAP intervention will undergo a series of sessions that include psychoeducation, adaptive cognitive training exercises, fatigue self-management strategies, and multidisciplinary content.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Apr 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 31, 2026
CompletedStudy Start
First participant enrolled
April 1, 2026
CompletedFirst Posted
Study publicly available on registry
April 15, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
April 1, 2027
April 15, 2026
March 1, 2026
7 months
March 31, 2026
April 7, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To determine whether the SuperCAP intervention program is superior to control in reducing disability.
Change in total WHODAS 2.0 score from baseline to post-intervention.
From baseline (week 0) to the post-intervention assessment (week 13).
Secondary Outcomes (16)
To assess whether the SuperCAP intervention leads to greater improvements in quality of life compared with control.
From baseline (week 0) to post-intervention (week 13)
To assess whether the SuperCAP intervention leads to greater improvements in instrumental daily functioning compared with control.
From baseline (week 0) to post-intervention (week 13).
To evaluate whether the intervention improves performance-based cognitive measures.
From baseline (week 0) to post-intervention (week 13).
To evaluate whether the intervention improves patient-reported cognitive functioning.
From baseline (week 0) to post-intervention (week 13).
To assess reductions in depressive symptoms following the intervention.
From baseline (week 0) to post-intervention (week 13)
- +11 more secondary outcomes
Study Arms (2)
SuperCAP Arm
EXPERIMENTALThe intervention comprises 60 sessions delivered over 12 weeks (5 sessions/week), with flexibility up to 15 weeks to accommodate symptom fluctuation. Each session follows a standardized structure to reinforce self-management and cognitive engagement. The sessions includes psychoeducation, adaptive cognitive training exercises, fatigue self-management strategies, and multidisciplinary content.
Standard of Care Arm
ACTIVE COMPARATORThe Standard of Care consists in a psychoeducational intervention on the cognitive disorders and fatigue associated with long COVID, and general guidelines on how to manage these symptoms so that they have the least possible impact on daily life.
Interventions
The psychoeducational intervention is a non-pharmacological interventions that teach practical strategies to help individuals with the cognitive disorders and fatigue associated with long COVID and provide general guidelines on how to manage these symptoms so that they have the least possible impact on daily life.
The SuperCAP (Supervised Computerized Active Program) is an online, multidimensional therapeutic program integrated into eSalut, the Catalan Institute of Health's digital platform, designed to improve daily functioning and quality of life in individuals with PCC who experience cognitive symptoms
Eligibility Criteria
You may qualify if:
- Diagnosis of PCC, defined as the presence of three or more symptoms associated with COVID-19 infection for at least three months, not explained by other diseases.
- Age 18 to 65 years.
- Willingness to participate in an app-based intervention program aimed at improving daily Functioning in People Living with PCC.
- Evidence of patient-reported cognitive difficulties emerging after COVID-19, operationalized as a WHODAS 2.0 Cognition Domain (D1) score \> 6 at baseline via RedCAP.
- Digital proficiency defined as scoring ≥4 on MDPQ-16 item 2a (sending emails) and ≥3 on item 6a (using the device's app store) via RedCAP.
- Self-reported ability to use a mobile application for approximately 15 minutes per day, 5 days per week, considering their current symptoms.
- Possession of a personal smartphone compatible with the study mobile application (eSalut), with sufficient storage space and operating system version required for installation.
You may not qualify if:
- Inability to undergo neuropsychological tests or additional assessments.
- Prior use of the SuperCAP program.
- Current participation in a trial or program aimed at improving PCC symptoms.
- Any condition that, in the investigator's opinion, could make participation unsafe, complicate interpretation of study results, interfere with achievement of study objectives, or otherwise affect the participant's ability to complete the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fundació Lluita contra les Infeccions - Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, 08916, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 31, 2026
First Posted
April 15, 2026
Study Start
April 1, 2026
Primary Completion (Estimated)
November 1, 2026
Study Completion (Estimated)
April 1, 2027
Last Updated
April 15, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share
The individual participant data (IPD) will not be shared publicly due to the nature of the study, the limited sample size, and the sensitive nature of the data related to cognitive status of the participants.